Short- and long-term effects induced by repeated 6-OHDA intraventricular administration: A new progressive and bilateral rodent model of Parkinson's disease.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Neuroscience

• Publication date

  2017-10-11

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1016/j.neuroscience.2017.08.017PMID 28823819
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Animal Models of Parkinson’s Disease

  2021cited by this paper
• Nonmotor features of Parkinson's disease subtypes

  2016cited by this paper
• Characterization of a new low‐dose 6‐hydroxydopamine model of Parkinson's disease in rat

  2016cited by this paper
• Systems-level neurophysiological state characteristics for drug evaluation in an animal model of levodopa-induced dyskinesia.

  2016cited by this paper
• Myricitrin Ameliorates 6-Hydroxydopamine-Induced Dopaminergic Neuronal Loss in the Substantia Nigra of Mouse Brain

  2016cited by this paper
• Early synaptic dysfunction in Parkinson's disease: Insights from animal models

  2016cited by this paper
• Investigation of tyrosine hydroxylase and BDNF in a low-dose rotenone model of Parkinson's disease.

  2015cited by this paper
• Molecular, Neurochemical, and Behavioral Hallmarks of Reserpine as a Model for Parkinson's Disease: New Perspectives to a Long‐Standing Model

  2015cited by this paper
• Dopaminergic, serotonergic, and noradrenergic deficits in Parkinson disease

  2015cited by this paper
• The 6-OHDA mouse model of Parkinson's disease - Terminal striatal lesions provide a superior measure of neuronal loss and replacement than median forebrain bundle lesions.

  2015cited by this paper
• Partial dopaminergic denervation-induced impairment in stimulus discrimination acquisition in parkinsonian rats: a model for early Parkinson's disease.

  2015cited by this paper
• Angiotensin type-1 receptor antagonists

  2015cited by this paper
• A partial lesion model of Parkinson's disease in mice--characterization of a 6-OHDA-induced medial forebrain bundle lesion.

  2015influential reference
• Dysautonomias in Parkinson's disease: cardiovascular changes and autonomic modulation in conscious rats after infusion of bilateral 6-OHDA in substantia nigra.

  2015cited by this paper
• From unilateral to bilateral parkinsonism: Effects of lateralization on dyskinesias and associated molecular mechanisms.

  2015influential reference
• Cardiovascular and autonomic alterations in rats with Parkinsonism induced by 6-OHDA and treated with L-DOPA.

  2015cited by this paper
• Pharmacological stimulation of metabotropic glutamate receptor type 4 in a rat model of Parkinson's disease and L-DOPA-induced dyskinesia: Comparison between a positive allosteric modulator and an orthosteric agonist.

  2015cited by this paper
• Alterations in the motor cortical and striatal glutamatergic system and D-serine levels in the bilateral 6-hydroxydopamine rat model for Parkinson's disease.

  2015cited by this paper
• Monoaminergic PET imaging and histopathological correlation in unilateral and bilateral 6-hydroxydopamine lesioned rat models of Parkinson's disease: a longitudinal in-vivo study.

  2015cited by this paper
• The expanding universe of disorders of the basal ganglia.

  2014cited by this paper
• A mouse model of non-motor symptoms in Parkinson's disease: focus on pharmacological interventions targeting affective dysfunctions

  2014cited by this paper
• Parkinson’s disease: animal models and dopaminergic cell vulnerability

  2014cited by this paper
• Early L-dopa, but not pramipexole, restores basal ganglia activity in partially 6-OHDA-lesioned rats.

  2014influential reference
• Reversal of haloperidol induced motor deficits in rats exposed to repeated immobilization stress.

  2014cited by this paper
• A survey from 2012 of evidence for the role of neuroinflammation in neurotoxin animal models of Parkinson's disease and potential molecular targets.

  2014cited by this paper
• Behavioral Characterization of A53T Mice Reveals Early and Late Stage Deficits Related to Parkinson’s Disease

  2013cited by this paper
• Levodopa improves motor deficits but can further disrupt cognition in a macaque parkinson model

  2013cited by this paper
• Age-Dependent Effects of A53T Alpha-Synuclein on Behavior and Dopaminergic Function

  2013cited by this paper
• LRRK2 knockout mice have an intact dopaminergic system but display alterations in exploratory and motor co-ordination behaviors

  2012cited by this paper
• Animal models of Parkinson’s disease

  2012cited by this paper
• Rosiglitazone, a PPAR-γ agonist, protects against striatal dopaminergic neurodegeneration induced by 6-OHDA lesions in the substantia nigra of rats.

  2012cited by this paper
• (G2019S) LRRK2 activates MKK4-JNK pathway and causes degeneration of SN dopaminergic neurons in a transgenic mouse model of PD

  2012cited by this paper
• Modeling of presymptomatic and symptomatic stages of parkinsonism in mice.

  2011cited by this paper
• Inter-hemispheric asymmetry of nigrostriatal dopaminergic lesion: a possible compensatory mechanism in Parkinson’s disease

  2011cited by this paper
• Longitudinal evolution of compensatory changes in striatal dopamine processing in Parkinson's disease.

  2011cited by this paper
• Vulnerability of Mesostriatal Dopaminergic Neurons in Parkinson's Disease

  2010cited by this paper
• Progression of dopaminergic depletion in a model of MPTP-induced Parkinsonism in non-human primates. An (18)F-DOPA and (11)C-DTBZ PET study.

  2010cited by this paper
• MPTP and SNpc DA neuronal vulnerability: Role of dopamine, superoxide and nitric oxide in neurotoxicity. Minireview.

  2009cited by this paper
• Modeling Parkinson's disease

  2009cited by this paper
• Initial clinical manifestations of Parkinson's disease: features and pathophysiological mechanisms.

  2009cited by this paper
• Striatal plasticity and basal ganglia circuit function.

  2008cited by this paper
• Behavioral Recovery in MPTP-Treated Monkeys: Neurochemical Mechanisms Studied by Intrastriatal Microdialysis

  2008cited by this paper
• Angiotensin type-1-receptor antagonists reduce 6-hydroxydopamine toxicity for dopaminergic neurons.

  2007influential reference
• Time‐course of nigrostriatal damage, basal ganglia metabolic changes and behavioural alterations following intrastriatal injection of 6‐hydroxydopamine in the rat: new clues from an old model

  2007cited by this paper
• A new model to study compensatory mechanisms in MPTP-treated monkeys exhibiting recovery.

  2007cited by this paper
• Rat model of Parkinson's disease with bilateral motor abnormalities, reversible with levodopa, and dyskinesias

  2007cited by this paper
• Stereology of Neural Connections: An Overview

  2006cited by this paper
• Comparison of bilaterally 6-OHDA- and MPTP-lesioned rats as models of the early phase of Parkinson's disease: histological, neurochemical, motor and memory alterations.

  2005cited by this paper
• Early administration of entacapone prevents levodopa-induced motor fluctuations in hemiparkinsonian rats.

  2005cited by this paper
• Neuroprotection induced by the adenosine A2A antagonist CSC in the 6-OHDA rat model of parkinsonism: effect on the activity of striatal output pathways

  2005cited by this paper
• Reductions in spontaneous locomotor activity in aged male, but not female, rats in a model of early Parkinson's disease.

  2005cited by this paper
• Effects of kappa receptor agonists on D1 and D2 dopamine agonist and antagonist-induced behaviors

  2005cited by this paper
• Effect of Bilateral 6-Hydroxydopamine Lesions of the Medial Forebrain Bundle on Reaction Time

  2002influential reference
• Animal models of neurological deficits: how relevant is the rat?

  2002cited by this paper
• Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway.

  2002cited by this paper
• Motor behavioural changes after intracerebroventricular injection of 6-hydroxydopamine in the rat: an animal model of Parkinson's disease.

  2001cited by this paper
• Dopamine cell degeneration induced by intraventricular administration of 6-hydroxydopamine in the rat: similarities with cell loss in parkinson's disease.

  2001cited by this paper
• Immunophilin ligands can prevent progressive dopaminergic degeneration in animal models of Parkinson's disease

  2001cited by this paper
• Relationship between the Appearance of Symptoms and the Level of Nigrostriatal Degeneration in a Progressive 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Lesioned Macaque Model of Parkinson's Disease

  2001cited by this paper
• Parallel Information Processing in the Dorsal Striatum: Relation to Hippocampal Function

  1999cited by this paper
• Effects of medial and lateral caudate-putamen lesions on place- and cue-guided behaviors in the water maze: relation to thigmotaxis.

  1999cited by this paper
• Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat.

  1998cited by this paper
• Differences in the reduced 18F-Dopa uptakes of the caudate and the putamen in Parkinson's disease: correlations with the three main symptoms.

  1996cited by this paper
• Dopaminergic neuronal degeneration and motor impairments following axon terminal lesion by instrastriatal 6-hydroxydopamine in the rat.

  1996cited by this paper
• Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by intrastriatal injection of 6-hydroxydopamine.

  1995cited by this paper
• Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat.

  1994influential reference
• Synergy between a selective D1 antagonist and a selective D2 antagonist in the induction of catalepsy.

  1989cited by this paper
• The organization of the projection from the cerebral cortex to the striatum in the rat.

  1989cited by this paper
• 6-Hydroxy-dopamine induced degeneration of central monoamine neurons.

  1968cited by this paper

• Preclinical Parkinson’s Disease Models for Non-Motor Symptoms: Research Recommendations from a Systematic Review

  2025cites this paper
• The 6-OHDA Parkinson’s Disease Mouse Model Shows Deficits in Sensory Behavior

  2024cites this paper
• Probable role of the hyperpolarization-activated current in the dual effects of CB1R antagonism on behaviors in a Parkinsonism mouse model.

  2022cites this paper
• Anti-Apoptotic and Anti-Inflammatory Role of Trans ε-Viniferin in a Neuron–Glia Co-Culture Cellular Model of Parkinson’s Disease

  2021cites this paper
• Study on the Regulation Effect of Optogenetic Technology on LFP of the Basal Ganglia Nucleus in Rotenone-Treated Rats

  2021cites this paper
• Behavioral Tests in Neurotoxin-Induced Animal Models of Parkinson’s Disease

  2020influential citation
• Motor impulsivity and delay intolerance are elicited in a dose-dependent manner with a dopaminergic agonist in parkinsonian rats

  2020cites this paper
• Effect of cerebral dopamine neurotrophic factor on endogenous neural progenitor cell migration in a rat model of Parkinson's disease

  2019cites this paper
• Pramipexole-induced impulsivity in mildparkinsonian rats: a model of impulse control disorders in Parkinson's disease.

  2019cites this paper
• Impulse control disorders in Parkinson’s disease

  2018cites this paper
• Insights into the Cyclooxygenase Pathway in a Progressive Rat Model of Parkinson’s Disease Induced by Prostaglandin J2: Protection with Ibuprofen

  2018cites this paper
• Flavonoids as Therapeutic Agents in Alzheimer's and Parkinson's Diseases: A Systematic Review of Preclinical Evidences

  2018cites this paper